Table 2 Characteristics related to prior and retreatment anti-EGFR regimens

  Response or stable disease ≥6 m

37/89 (42)

  No response or stable disease <6 m

52/89 (58)

Clinical benefit on anti-EGFR retreatment

  Best response CR/PR/SD

50/86 (58)

  Best response PD

36/86 (42)

Prior anti-EGFR-based regimens

  Panitumumab monotherapy

6/89 (7)

  Panitumumab + Chemotherapy^a

9/89 (10)

  Panitumumab and AMG-102/AMG-479

1/89 (1)

  Cetuximab monotherapy

2/89 (2)

  Cetuximab + Chemotherapy^b

71/89 (80)

Anti-EGFR-based retreatment regimens

  Cetuximab, FOLFOX, and dasatinib

31/89 (35)

  Cetuximab, irinotecan, and bevacizumab

12/89 (13)

  Cetuximab and erlotinib

13/89 (15)

  Cetuximab and sirolimus

11/89 (12)

  Cetuximab, HAI^c oxaliplatin, 5-FU, bevacizumab

20/89 (23)

  Cetuximab, HAI oxaliplatin, and bevacizumab

2/89 (2)

Interval length between prior and retreatment anti-EGFR therapies

Months

  Median

4.57

  Mean ± Standard Deviation

7.34 ± 8.9

  Range

0.46 – 58.7